Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund Regular Growth
EquityIndex FundsVery High Risk
Regular
NAV (17-Jun-25)
Returns (Since Inception)
Fund Overview
Fund Size
₹156 Cr
Expense Ratio
1.05%
ISIN
INF754K01LR3
Minimum SIP
₹100
Exit Load
No Charges
Inception Date
26 Oct 2020
About this fund
As of 17-Jun-25, it has a Net Asset Value (NAV) of ₹19.12, Assets Under Management (AUM) of 156.35 Crores, and an expense ratio of 1.05%.
- Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund Regular Growth has given a CAGR return of 15.00% since inception.
- The fund's asset allocation comprises around 99.93% in equities, 0.00% in debts, and 0.07% in cash & cash equivalents.
- You can start investing in Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund Regular Growth with a SIP of ₹100 or a Lumpsum investment of ₹100.
Performance against Category Average
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+6.71%
— (Cat Avg.)
3 Years
+20.51%
— (Cat Avg.)
Since Inception
+15.00%
— (Cat Avg.)
Portfolio Summaryas of 31st May 2025
| Equity | ₹156.25 Cr | 99.93% |
| Others | ₹0.1 Cr | 0.07% |
Top Holdings
All Holdings
Equity
Debt & Others
| Name | Type  | Amount | Holdings |
|---|---|---|---|
| Sun Pharmaceuticals Industries Ltd | Equity | ₹19.22 Cr | 12.29% |
| Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹10.44 Cr | 6.68% |
| Divi's Laboratories Ltd | Equity | ₹9.43 Cr | 6.03% |
| Cipla Ltd | Equity | ₹9.18 Cr | 5.87% |
| Dr Reddy's Laboratories Ltd | Equity | ₹8.72 Cr | 5.58% |
| Apollo Hospitals Enterprise Ltd | Equity | ₹8.27 Cr | 5.29% |
| Eli Lilly and Co | Equity | ₹7.6 Cr | 4.86% |
| Lupin Ltd | Equity | ₹5.33 Cr | 3.41% |
| Johnson & Johnson | Equity | ₹4.77 Cr | 3.05% |
| Torrent Pharmaceuticals Ltd | Equity | ₹4.49 Cr | 2.87% |
| AbbVie Inc | Equity | ₹4.2 Cr | 2.68% |
| Fortis Healthcare Ltd | Equity | ₹4.14 Cr | 2.65% |
| Mankind Pharma Ltd | Equity | ₹3.65 Cr | 2.33% |
| Aurobindo Pharma Ltd | Equity | ₹3.58 Cr | 2.29% |
| Novo Nordisk AS ADR | Equity | ₹2.94 Cr | 1.88% |
| Abbott Laboratories | Equity | ₹2.93 Cr | 1.87% |
| Novartis AG ADR | Equity | ₹2.91 Cr | 1.86% |
| Zydus Lifesciences Ltd | Equity | ₹2.79 Cr | 1.79% |
| Laurus Labs Ltd | Equity | ₹2.55 Cr | 1.63% |
| Alkem Laboratories Ltd | Equity | ₹2.55 Cr | 1.63% |
| Intuitive Surgical Inc | Equity | ₹2.51 Cr | 1.61% |
| Merck & Co Inc | Equity | ₹2.48 Cr | 1.59% |
| Glenmark Pharmaceuticals Ltd | Equity | ₹2.45 Cr | 1.57% |
| Ipca Laboratories Ltd | Equity | ₹2.37 Cr | 1.52% |
| Amgen Inc | Equity | ₹1.98 Cr | 1.26% |
| Thermo Fisher Scientific Inc | Equity | ₹1.97 Cr | 1.26% |
| Gilead Sciences Inc | Equity | ₹1.72 Cr | 1.10% |
| Biocon Ltd | Equity | ₹1.68 Cr | 1.07% |
| Stryker Corp | Equity | ₹1.67 Cr | 1.07% |
| GlaxoSmithKline Pharmaceuticals Ltd | Equity | ₹1.67 Cr | 1.07% |
| Danaher Corp | Equity | ₹1.57 Cr | 1.01% |
| Narayana Hrudayalaya Ltd | Equity | ₹1.48 Cr | 0.95% |
| Piramal Pharma Ltd | Equity | ₹1.47 Cr | 0.94% |
| Vertex Pharmaceuticals Inc | Equity | ₹1.45 Cr | 0.93% |
| Gland Pharma Ltd | Equity | ₹1.41 Cr | 0.90% |
| Syngene International Ltd | Equity | ₹1.4 Cr | 0.89% |
| Medtronic PLC | Equity | ₹1.36 Cr | 0.87% |
| Ajanta Pharma Ltd | Equity | ₹1.31 Cr | 0.84% |
| Cohance Lifesciences Ltd | Equity | ₹1.27 Cr | 0.81% |
| Global Health Ltd | Equity | ₹1.14 Cr | 0.73% |
| Regeneron Pharmaceuticals Inc | Equity | ₹0.67 Cr | 0.43% |
| Becton Dickinson & Co | Equity | ₹0.64 Cr | 0.41% |
| Agilent Technologies Inc | Equity | ₹0.41 Cr | 0.26% |
| IQVIA Holdings Inc | Equity | ₹0.33 Cr | 0.21% |
| Clearing Corporation Of India Ltd. | Cash - Repurchase Agreement | ₹0.18 Cr | 0.12% |
| Illumina Inc | Equity | ₹0.17 Cr | 0.11% |
| Net Receivables/(Payables) | Cash - Collateral | ₹-0.08 Cr | 0.05% |
| Accrued Interest | Cash - Repurchase Agreement | ₹0 Cr | 0.00% |
Allocation By Market Cap (Equity)
Large Cap Stocks
34.43%
Mid Cap Stocks
31.23%
Small Cap Stocks
5.96%
Other Allocation
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹156.25 Cr | 99.93% |
Risk & Performance Ratios
Standard Deviation
This fund
12.76%
Cat. avg.
--
Lower the better
Sharpe Ratio
This fund
0.79
Cat. avg.
--
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
--
Higher the better
Fund Managers
Bhavesh Jain
Since October 2021
Amit Vora
Since February 2021
Additional Scheme Detailsas of 31st May 2025
ISIN | INF754K01LR3 | Expense Ratio | 1.05% | Exit Load | No Charges | Fund Size | ₹156 Cr | Age | 4 years 7 months | Lumpsum Minimum | ₹100 | Fund Status | Open Ended Investment Company | Benchmark | MSCI Ind Dom & Wld HealthC 45 NR INR |
Investment Objective
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Tax Treatment
Capital Gains Taxation:
- If units are sold after 1 year from the date of investment: Gains up to INR 1.25 lakh in a financial year are exempt from tax. Any gains exceeding INR 1.25 lakh are taxed at a rate of 12.5%.
- If units are sold within 1 year from the date of investment: The entire amount of gain is taxed at a rate of 20%.
- Holding the units: No tax is applicable as long as you continue to hold the units.
Dividend Taxation:
Dividends are added to the investor’s income and taxed according to their respective tax slabs. Additionally, if an investors dividend income exceeds INR 5,000 in a financial year, the fund house deducts a 10% Tax Deducted at Source (TDS) before distributing the dividend.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Similar Index Funds Funds
| Fund name | Expense Ratio | Exit Load | Fund size | 1Y  |
|---|---|---|---|---|
| Motilal Oswal Nifty PSE ETF Very High Risk | - | - | - | - |
| Groww Nifty 500 Low Volatility 50 ETF Very High Risk | - | - | - | - |
| Nippon India BSE Sensex Next 30 Index Fund Direct Growth Very High Risk | - | 0.0% | - | - |
| Nippon India BSE Sensex Next 30 Index Fund Regular Growth Very High Risk | - | 0.0% | - | - |
| Motilal Oswal BSE India Infrastructure ETF Very High Risk | - | - | ₹5.21 Cr | - |
| Nippon India BSE Sensex Next 30 ETF Very High Risk | - | - | - | - |
| ICICI Prudential Nifty200 Quality 30 Index Fund Direct Growth Very High Risk | - | 0.0% | - | - |
| ICICI Prudential Nifty200 Quality 30 Index Fund Regular Growth Very High Risk | - | 0.0% | - | - |
| Motilal Oswal Nifty Next 50 ETF Very High Risk | - | - | ₹2.78 Cr | - |
| SBI NIFTY 200 Quality 30 Index Fund Direct Growth Very High Risk | - | 0.0% | - | - |
About the AMC
Total AUM
₹1,76,896 Cr
Address
J.P.Morgan Tower, Mumbai, 400 098
Other Funds by Edelweiss Mutual Fund
Risk Level
Your principal amount will be at Very High Risk
Unlock Expert Insights!
Related Articles
Still got questions?
We're here to help.
What is the current NAV of Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund Regular Growth?
What are the returns of Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund Regular Growth?
What is the portfolio composition of Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund Regular Growth?
Who manages the Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund Regular Growth?
- Bhavesh Jain
- Amit Vora
Dezerv Investments Private Limited is a Portfolio Manager with SEBI Registration no. INP000007377 and an Investment Manager to Category - I AIF-VCF-Angel Fund with SEBI Registration no. IN/AIF1/22-23/1066.
Mutual Fund distribution services are offered through Dezerv Distribution Services Pvt Limited, a wholly owned subsidiary with AMFI Registration No.: ARN -248439. **Mutual fund investments are subject to market risks, read all scheme related documents carefully.** Terms and conditions of the website are applicable. Privacy policy of the website is applicable.